NCT07491328 Liquid Biopsy in Paraneoplastic Neurological Syndromes
| NCT ID | NCT07491328 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Heinrich-Heine University, Duesseldorf |
| Condition | Paraneoplastic Neurological Syndromes |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-05-20 |
| Primary Completion | 2030-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2023-05-20 with a primary completion date of 2030-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
Eligibility Criteria
Inclusion Criteria: * Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies or * Patients with peripheral tumors without PNS Exclusion Criteria: * Age below 18 years at the time of inclusion. * Any mental condition impairing the capacity to provide informed consent. * Presence of contraindications to DLA.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07491328 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Paraneoplastic Neurological Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07491328 currently recruiting?
Yes, NCT07491328 is actively recruiting participants. Contact the research team at nico.melzer@med.uni-duesseldorf.de for enrollment information.
Where is the NCT07491328 trial being conducted?
This trial is being conducted at Düsseldorf, Germany.
Who is sponsoring the NCT07491328 clinical trial?
NCT07491328 is sponsored by Heinrich-Heine University, Duesseldorf. The trial plans to enroll 60 participants.